New gut implant aims to tackle diabetes and obesity without surgery
NCT ID NCT07417683
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a temporary device placed in the upper small intestine to help control type 2 diabetes and obesity. The implant stays for 6 months and is then removed. Researchers will check if it lowers blood sugar (HbA1c), helps with weight loss, and improves liver health in people with MASH. About 126 adults will take part, with regular clinic visits and follow-up after removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
endoscopic implant (gastroduodenal bypass liner)
What this could lead to
If it works, this could offer a non-surgical, reversible option to help control diabetes and obesity, and possibly improve liver health in MASH patients.
What could go wrong
This is an early approval study with only 126 participants, so results may not apply to everyone. The implant requires endoscopic placement and removal, and there may be side effects or complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charite Universitätmedizin Berlin CVK
Berlin, 13353, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum St. Georg Leipzig
Leipzig, Saxony, 04129, Germany
Contact Phone: •••-•••-••••
-
Knappschaft Kliniken Universitätsklinikum Bochum GmbH Medizinische Klinik
Bochum, North Rhine-Westphalia, 44892, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sozialstiftung Bamberg
Bamberg, Bavaria, 96049, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Städtisches Klinikum Dresden
Dresden, Saxony, 01067, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Leipzig Medical Center, Department of Oncology, Gastroenterology, Hepatology and Pneumology
Leipzig, Saxony, 04103, Germany
-
Universitätsklinikum Würzburg
Würzburg, Bavaria, 97080, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsmedizin Mannheim
Mannheim, Baden-Wurttemberg, 68167, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••